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Abstract: Fragile X syndrome (FXS) is the most common genetic cause of intellectual  disability 
and the most common single-gene cause of autism. It is caused by mutations on the fragile 
X mental retardation gene (FMR1) and lack of fragile X mental retardation protein, which in 
turn, leads to decreased inhibition of translation of many synaptic proteins. The metabotropic 
glutamate receptor (mGluR) hypothesis states that the neurological deficits in individuals with 
FXS are due mainly to downstream consequences of overstimulation of the mGluR pathway. 
The main efforts have focused on mGluR5 targeted treatments; however, investigation on the 
gamma-aminobutyric acid (GABA) system and its potential as a targeted treatment is less 
emphasized. The fragile X mouse models (Fmr1-knock out) show decreased GABA subunit 
receptors, decreased synthesis of GABA, increased catabolism of GABA, and overall decreased 
GABAergic input in many regions of the brain. Consequences of the reduced GABAergic input 
in FXS include oversensitivity to sensory stimuli, seizures, and anxiety. Deficits in the GABA 
receptors in different regions of the brain are associated with behavioral and attentional processing 
deficits linked to anxiety and autistic behaviors. The understanding of the neurobiology of FXS 
has led to the development of targeted treatments for the core behavioral features of FXS, which 
include social deficits, inattention, and anxiety. These symptoms are also observed in individuals 
with autism and other neurodevelopmental disorders, therefore the targeted treatments for FXS 
are leading the way in the treatment of other neurodevelopmental syndromes and autism. The 
GABAergic system in FXS represents a target for new treatments. Herein, we discuss the animal 
and human trials of GABAergic treatment in FXS. Arbaclofen and ganaxolone have been used 
in individuals with FXS. Other potential GABAergic treatments, such as riluzole, gaboxadol, 
tiagabine, and vigabatrin, will be also discussed. Further studies are needed to determine the 
safety and efficacy of GABAergic treatments for FXS.
Keywords: gamma-aminobutyric acid (GABA) system, targeted treatments, autism, ganax-
olone, arbaclofen
Introduction
Fragile X syndrome (FXS) is the most common cause of inherited intellectual 
disability and largest single-gene cause of autism.1 The fragile X mental retarda-
tion gene (FMR1) located on the X chromosome at band q27.3 typically has 5–44 
CGG repeats; however, this trinucleotide repeat length can expand to an unstable 
repeat length. 45-54 CGG repeats is considered a gray zone and may have some 
clinical involvement, including a higher rate of primary ovarian insufficiency com-
pared to controls.2 Premutation carriers have trinucleotide repeats ranging from 
55–200 CGG in length. These are usually healthy individuals who are at risk of 
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developing fragile X-associated tremor/ataxia syndrome, a 
neurodegenerative disorder seen in aging carriers.3 They are 
also at an increased risk for anxiety and mood disorders,4 
immune-mediated disorders,5 migraine headaches,6 
hypertension,7 and primary ovarian insufficiency,8 all of 
which range in severity and prevalence. Adult female car-
riers have evidence of gamma-aminobutyric acid (GABA) 
dysfunction.9
There are some carriers who may show an attention-
deficit hyperactivity disorder (ADHD) and autism spectrum 
disorders (ASDs);10 however, the prevalence of those traits 
is far more common in individuals with the full mutation 
whose trinucleotide expansion is greater than 200 CGG 
repeats. The full mutation presents with a range of clini-
cal features, including ADHD, ASDs, anxiety, intellectual 
disability, social avoidance, aggression, stereotyped behav-
iors, disrupted sleep patterns, epilepsy, macroorchidism, 
prominent ears, long faces, soft skin, and hyperextensible 
joints.11 Males with the full mutation are typically more 
severely affected than females due to the compensatory 
nature of the second X chromosome, which still translates 
the FMR1 gene leading to more normal fragile X mental 
retardation protein (FMRP) production. The prevalence 
of the full mutation is approximately one in 5,000 males12 
and one in 8,000 females,13 whereas the premutation is 
far more common, at one in 130–250 females and one in 
250–810 males.14
The expansion of the trinucleotide sequence results in 
lowered FMRP levels. The premutation expansion results 
in a two- to eightfold increase in FMR1 mRNA levels, 
which leads to RNA toxicity accounting for phenotypic 
features; however, the FMRP levels often stay normal 
or become somewhat decreased, particularly after 120 
CGG repeats.15,16 The full mutation results in reduced or 
no FMRP production, which is found primarily in the 
brain and testes. In the brain, FMRP is crucial to synaptic 
development and refinement thus accounting for the psy-
chiatric features of FXS, while its presence in the testes 
is needed for normal testicular size. The primary function 
of FMRP is to negatively regulate protein translation at 
the synapse,17 and it is estimated that FMRP binds up to 
4%–8% of mRNA within the brain.18 This regulation is 
crucial in the metabotropic glutamate receptors (mGluRs) 
1 and 5, which become upregulated, leading to exagger-
ated long-term depression (LTD). This concept is the 
basis of the mGluR theory of FXS19 and the focus of many 
targeted treatments for FXS, such as the mGluR5 antago-
nists AFQ056 (mavoglurant; Novartis  Pharmaceuticals, 
Basel, Switzerland) and RO4917523 (F Hoffmann-La 
Roche AG, Basel, Switzerland). 
Additionally implicated in the dysregulation at the 
synapse is the GABA system, which is important in syn-
aptic inhibition. An imbalance between the excitatory 
glutamatergic and the inhibitory GABAergic neurotrans-
mission is proposed to cause the cognitive impartments, 
anxiety, and autism of FXS and other neuropsychiatric and 
neurodevelopmental disorders.1,20,21 While two medications 
have been developed specifically for GABAergic modula-
tion – arbaclofen (Seaside Therapeutics, Cambridge, MA, 
USA) and ganaxolone (Marinus Pharmaceuticals, Inc., New 
Haven, CT, USA) – this paper will also address GABAergic 
medications such as riluzole, gaboxadol, tiagabine, and 
vigabatrin. Before discussing the medications, a more in-
depth focus on the GABA system and its dysregulation in 
FXS will follow.
Neurobiology
More than 3 decades of molecular research have led to a 
better understanding of the neurobiology of FXS and related 
disorders. FXS is caused by a dynamic mutation of more 
than 200 CGG trinucleotide repeats in the 5’ untranslated 
region on the FMR1 gene, which results in an absence of 
expression of FMRP. FMRP is a selective RNA-binding 
protein, found most abundantly in the CNS and testes, 
which regulates the expression of many mRNAs through 
inhibitory control at the synapse.22 The crucial role of FMRP 
in regulating the synthesis of synaptic proteins extends 
beyond the phenotype of FXS to other neurodevelopmental 
and neuropsychiatric disorders, in which FMRP may also 
be deficient.23
FMRP contains three main RNA-binding domains: two 
hnRNP K-homology domains and one arginine- and glycine-
rich region of FMRP. In vitro FMRP is part of messenger 
ribonucleoparticles (structures that are involved in protein 
synthesis) and regulates dendritic transport of associated 
mRNAs.22 FMRP interacts with several cytoplasmic and 
nuclear proteins and has been found in granules containing 
translationally silent preinitiation complexes. In summary, 
FMRP regulates RNA transportation, stabilization, and transla-
tion, mainly at the synapse in neurons.
The activation of mGluR5 induces protein synthesis in 
the soma, axons, dendrites, and postsynaptic sites, as well 
as degradation and recycling of somatic and axonic proteins 
through the MAPK/ERK and mTOR pathways, which is 
required for LTD, a form of hippocampal synaptic plasticity 
that develops and consolidates long-term memories. In the 
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Fmr1-knock out [KO] mice, LTD is significantly increased, 
and this leads to deficits in synaptic plasticity and weaken-
ing of synaptic connections.22 The mGluR theory, which 
suggests that psychiatric and neurological aspects of the 
syndrome are due to exaggerated downstream consequences 
of mGluR5 upregulation, was validated by genetic mouse 
studies in which rescue of several symptoms occurred when 
the Fmr1-KO mouse was crossed with the mGluR heterozy-
gous mouse.24 The Fmr1-KO also shows hypothalamic excess 
of many synaptic proteins from increased protein translation 
rate and protein synthesis, whereas the GABA system is 
downregulated in the absence of FMRP, as described in the 
GABA neurobiology section.25
GABA neurobiology
The GABA system is the main inhibitory system in the brain. 
It works through two classes of GABA receptors: GABA
A
 
and GABA
B
. GABA
A
 receptors are ligand-gated ion channels, 
whereas GABA
B
 receptors are G protein-coupled receptors. 
GABA
A
 receptors allow the flow of chloride ions across the 
membrane, which hyperpolarizes the neuron’s postsynaptic 
membrane and minimizes the effect of any coincident syn-
aptic input. GABA
B
 receptors hyperpolarize the neuron’s 
membrane by activating G-protein-coupled inwardly recti-
fying potassium channels.26 The GABA receptors are very 
diverse in their subunit composition and localization at the 
synapse and in regions of the brain; their effects are fast or 
slow persistent-tonic inhibition, depending on their localiza-
tion and grade of stimulation.27
The GABA system is required for a balanced neuronal 
activation and network oscillations, direct flow of informa-
tion, neural synchrony, and facilitating the movement of 
information in and between multiple brain areas involved 
in cognition.28–30 Since FXS is characterized by anxiety, 
hyperarousal, and epilepsy,31,32 recent studies33–36 have aimed 
to identify the defects in the inhibitory GABA system in the 
Fmr1-KO mouse.
GABAA
FMRP targets the mRNAs encoding eight different GABA
A
 
receptor subunits (α1, α3, α4, β1, β2, γ1, γ2, and δ), which 
were significantly reduced in the neocortex and cerebellum 
of Fmr1-KO mice, particularly the γ subunit, which rep-
resents extrasynaptic (perisynaptic) GABA
A
 receptors.37,38 
The Fmr1-KO mouse confirms a deficit in the production 
of GABA
A
 receptors. Proteins required for GABA transport 
(eg, GABA transporter) and catabolism (eg, GABA transami-
nase [GABA-T], succinic semialdehyde [SSADH]) are also 
reduced.33,34 In addition, FMRP in the presynaptic side also 
regulates the expression of glutamic acid decarboxylase, 
which is the rate-limiting GABA-synthesis enzyme.33,35,37 
Therefore, FMRP regulates the expression, metabolism, and 
catabolism of the GABA
A
 receptors, and in its absence, there 
is a decreased GABAergic input. The Fmr1-KO mouse exhib-
its reduced inhibitory postsynaptic currents in the amygdala35 
and subicular neurons.36 Although FMRP inhibits the transla-
tion of many messages, it can also stimulate the translation 
of mRNAs, and the GABA system is downregulated in the 
absence of FMRP. Consequences of the reduced GABA
A
 
receptor expression in FXS likely include oversensitivity to 
sensory stimuli, seizures, and anxiety.
GABAB
GABA
B
 is a metabotropic G protein-coupled receptor that 
regulates voltage-gated Ca2+ channels, G protein inwardly 
rectifying K+ channels, and adenylyl cyclase.26 Activation of 
the receptor triggers slow inhibitory postsynaptic currents, 
which reduce the neuronal excitability.26 Presynaptic GABA
B
 
receptors inhibit glutamate release, which further exacerbates 
the upregulation of the mGluR5 system;  therefore, treat-
ment with GABA
B
 modulators has the potential to correct 
phenotypic deficits in FXS. When treated with a double-
knockout of FMR1 and RGS4, male Fmr1-KO mice showed 
reduced susceptibility to audiogenic seizures.39 Since RGS4 
is a regulator of G protein signaling and associated with 
GABA
B
 receptors and inward-rectifying K+ channels, it has 
a therapeutic potential to regulate GABA
B
 subunits in the 
treatment of FXS.39
Impacted regions of the brain
The amygdala, a component of the limbic system involved in 
emotional recognition and reaction, as well as fear processing, 
is one part of the brain considerably impacted by GABAergic 
dysregulation. Socioemotional impairments are prevalent 
in both premutation and full mutation patients, which war-
rants study of the amygdala as a basis for this impairment. 
Numerous studies have been performed assessing amygdala 
volume, activation in relation to gaze processing, and 
facial-emotional processing, which yield contradictory and 
inconsistent results due to varied protocols and populations 
(as summarized in Kim et al).40 Fear-specific activation of 
the amygdala was significantly reduced in patients with FXS 
compared to neurotypical controls, despite no differences in 
amygdala volume,40 which suggests biological impairment 
possibly at the synaptic level instead of altered brain size 
leading to emotional dysregulation. The amygdala’s phasic 
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inhibitory postsynaptic currents, tonic inhibitory currents, 
reduced GABA release, and inhibitory synapses are consid-
erably reduced in frequency and amplitude in the amygdala 
of Fmr1-KO mice.35 Due to the phenotypic socioemotional 
impairments seen in both the premutation and full mutation 
individuals alongside the biological impairments seen in 
the Fmr1-KO mouse, the amygdala is a point of study for 
gauging improvement with new treatments.
Further modifications in GABAergic activity are found 
in the cortex of the brain in FXS and, while monosynaptic 
GABAergic transmission is unaffected, there is a substan-
tial deficit in local excitatory drive targeting fast-spiking 
inhibitory neurons in layer 4 of the somatosensory (barrel) 
cortex, which partially accounts for seizures, cognitive 
dysfunction, and sensory hypersensitivity of the FXS 
phenotype.41
A study assessing GABA-mediated cerebellar inhibi-
tion comparing healthy, asymptomatic women with and 
without the premutation found that women with the pre-
mutation show an absence of cerebellar inhibition over 
primary motor cortex as well as reduced GABA
A
-mediated 
intracortical and afferent inhibition.9 Even in asymptomatic 
carriers, there is still GABA dysregulation, which warrants 
the need for compounds with GABAergic modulation prop-
erties in premutation carriers. The available compounds 
are limited and mostly focus on antiepileptic properties; 
however, other mechanisms of action modified by such 
treatments may provide additional outlets for improving 
the phenotype in both carriers and individuals affected by 
the full mutation.
GABAergic treatments
After a better understanding of the neurobiology and neuro-
pathogenesis of FXS, many compounds have been used as 
targeted treatments for FXS. Research has focused mainly 
on the development of mGluR5 antagonists, but better 
understanding of the GABAergic system in FXS has led to 
a new GABAergic approach and relevant targeted treatment. 
The GABA receptors in different regions of the brain are 
associated with some behavioral phenotypes in individuals 
with FXS. Particular attention has been devoted to correcting 
the amygdala-based symptoms. GABAergic agonists can 
be used for specific phenotypes including anxiety, autistic 
 behavior, epilepsy, and cognitive impairment. GABA ago-
nists have shown very limited efficacy in preliminary studies 
for these symptoms, but they have been well tolerated.42,43 
The GABAergic treatments are a relatively new area and 
basic and translational research is limited in spite of their 
potential to treat FXS based on animal and small clinical 
studies. 
Acamprosate
Acamprosate is a GABA
A
 agonist approved for treatment of 
alcohol withdrawal. Excessive alcohol consumption over a 
long period of time changes the balance between the excit-
atory and inhibitory systems. Acamprosate helps people who 
have consumed large amounts of alcohol by stabilizing the 
excitatory/inhibitory balance in the brain, mainly by enhanc-
ing the function of GABA
A
 receptors and, possibly, by its 
inhibitory effects on the mGluRs.44 Acamprosate does not 
prevent the withdrawal symptoms that people may experience 
when they stop drinking alcohol.
Clinically, a short report of three patients with FXS treated 
with acamprosate showed improvements in language and 
behavior,44 which led to other GABAergic targeted treatments 
and a second open-label 10-week trial of acamprosate (mean 
dose 1,054±422 mg/day) in 12 children and adolescents 
ages 6 to 17 years with FXS. The study showed improve-
ments in social behavior and inattention/ hyperactivity using 
multiple standard behavioral outcome measures. A Clinical 
Global Impressions-Improvement (CGI-I) scale score of 
“very much improved” or “much improved” was rated in 
nine of 12 (75%) subjects. No significant adverse effects 
were reported. Additionally, pre- and posttreatment blood 
biomarker analyses were performed by measuring brain-
derived neurotrophic factor (BDNF) levels. A significant 
increase in the BDNF levels with treatment was described. 
However, treatment response did not correlate with change 
in the BDNF level.44
Ganaxolone
Ganaxolone (3a-hydroxy-3B-methyl analog of allopreg-
nanolone) is a GABA
A
 receptor agonist through allosteric 
modulation that has anticonvulsant, anxiolytic, and seda-
tive effects.45 It is orally active and does not have hormonal 
effects. Neuroactive steroids like ganaxolone act most 
potently and effectively on GABA
A
 receptors containing 
δ subunits. Ganaxolone is under development for treatment 
of seizure disorders and posttraumatic stress disorder. This 
pharmaceutical has been well tolerated, is safe in adults, 
child ren, and infants,46 and has been found to improve symp-
toms in humans and mouse models.46,47
Although many GABA
A
 receptor subtypes are diminished 
in the Fmr1-KO mouse, there is evidence that  extrasynaptic γ 
subunit containing GABA
A
 receptors are especially affected.48 
In the Fmr1-KO, ganaxolone has been shown to decrease 
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audiogenic seizures.47 Similarly, studies in the dfmr mutant fly 
showed that GABA
A
 agonists ameliorate the lethality phenotype 
of glutamate-containing food, neuropathology, excessive pro-
tein translation, and abnormal courtship behavior.49 The most 
frequently reported adverse events with ganaxolone in seizure 
studies are somnolence, convulsion, agitation, pharyngitis, otitis 
media, diarrhea, vomiting, cough, and pyrexia.50 A randomized, 
Phase II, double-blind, placebo-controlled crossover trial to 
investigate the efficacy of ganaxolone for the treatment of anxi-
ety and attention deficits in children with FXS aged 6 to 17 years 
(http://www.ClinicalTrials.gov; NCT01725152)51 is currently 
under way. Ganaxolone should increase and normalize GABA
A
-
mediated signaling – by boosting the signaling capacity of 
existing receptors – and improve behavior, particularly anxiety 
and attention.
Gaboxadol (THiP)
Tonic GABA
A
 inhibition is associated with specific recep-
tor subunits, particularly the relatively rare α4, α6, and 
δ subunits. The δ subunit-containing receptors are insen-
sitive to benzodiazepine agonists,52,53 but highly sensitive 
to gaboxadol.54,55 Gaboxadol, the selective δ-GABA
A
 
super-agonist receptor, 4,5,6,7-tetrahydroisoxazolo(5,4-c)
pyridin-3-ol (also known as THIP), has properties to generate 
tonic inhibition, namely activation by low concentrations of 
GABA through the activation of the extrasynaptic δ subunit-
containing receptors.54,56
As previously mentioned, Fmr1-KO mouse studies have 
showed deficits in inhibitory transmission in the amygdala 
of the Fmr1-KO mouse, including reduction in the frequency 
and amplitude of phasic inhibitory postsynaptic currents 
and of tonic inhibitory currents, as well as a reduction in the 
number of inhibitory synapses and in neuronal hyperexcit-
ability in principal neurons.35
A neuronal study has also shown significant increases in 
the action potential threshold in both wild-type and Fmr1-KO 
mice.57  Strikingly, the action potential threshold in Fmr1-KO 
mice in amygdala slices was restored to wild-type levels by 
THIP application. Thus, the electrophysiological abnormalities 
of neuronal hyperexcitability in the Fmr1-KO amygdala can 
be dramatically rescued by augmenting tonic inhibitory tone.35 
A behavioral study in Fmr1-KO mice have shown that THIP 
significantly attenuated hyperactivity and reduced prepulse 
inhibition in a volume-dependent manner. However, THIP 
did not reverse the deficits in cued fear or startle response.58 
Current studies show that enhancing GABAergic transmission 
can correct specific behavioral phenotypes of the Fmr1-KO 
mouse, further supporting focus on the GABAergic system 
and, specifically, tonic inhibition, which might be important for 
correcting or ameliorating specific behaviors in FXS.47,49,58
Gaboxadol reached a Phase III trial before its ces-
sation because of side effects, such as hallucination and 
 disorientation. Due to these safety concerns and lack of effi-
cacy, work on the drug was discontinued in 2007; however, 
recent studies in animal models of ASD have shown that 
gaboxadol is effective in rescuing neurophysiological and 
behavioral deficits.58,59 Further studies in fragile X animal 
models are necessary to provide cumulative evidence in the 
efficacy and safety of gaboxadol. Currently, there are no 
studies in individuals with FXS.
vigabatrin
Vigabatrin is an antiepileptic and analog of GABA 
(although not an agonist) that inhibits the catabolism of 
GABA by irreversibly inhibiting GABA transaminase. It 
has been found that the half-life of biologic activity is far 
longer than the elimination half-life,60,61 and there is no 
range of target concentrations because there was no differ-
ence between the serum concentration levels of responders 
and those of nonresponders.61 In addition, the duration 
of action is more a function of the GABA transaminase 
resynthesis rate.62 Vigabatrin has been approved by the US 
Food and Drug Administration (FDA) for use in patients 
with refractory complex partial seizures, but the rentinal 
toxicity of the medication limits it’s use to those who have not 
responded to other treatments.63 However, it is recommended 
when the benefits outweigh the side effects in individuals 
with intractable  seizures. There are no studies in FXS animal 
models or clinical trials in individuals with FXS.
Arbaclofen
One compound shown to influence GABA regulation in the 
Fmr1-KO mouse is arbaclofen, a GABA
B
 agonist developed 
by Seaside Therapeutics. Arbaclofen is a receptor agonist and 
active enantiomer of racemic baclofen, which presynaptically 
blocks glutamate release, thereby decreasing the overacti-
vation of the glutamatergic pathways. In Fmr1-KO mice, 
arbaclofen corrected elevated protein synthesis in the hip-
pocampus; reduced elevated AMPA (α-Amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid) receptor internalization to 
wild-type values; decreased mRNA translation in the cortex; 
and corrected the increased spine density prevalent in the 
mouse phenotype.64
In pediatric, adolescent, and adult patients with FXS, arba-
clofen was administered in a randomized, double-blind, placebo-
controlled crossover study. The primary outcome measure, the 
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Figure 1 Neurobiology in FXS.
Notes: (A) in the normal neurobiology of the synapse, FMRP regulates the expression of GABA receptors and the metabolism and catabolism of GABA. (B) The affected 
neurobiology in FXS, with reduced GABA synthesis and transport, fewer GABAA and GABAB receptors, and therefore overall reduced GABAergic activity. (C) The 
neurobiology in FXS with GABAergic treatments. The sites of action for the medications are indicated by stars on the various receptors and enzymes. Arbaclofen focuses on 
the presynaptic GABAB receptors to increase their activity with a secondary inhibitory effect on the presynaptic release of glutamate. Ganaxolone, acamprosate, and riluzole 
all work on the GABAA receptors to increase the reduced activity. Ganaxolone, however, has higher affinity to the extrasynaptic δ subunit containing GABAA receptors. 
vigabatrin reduces the resynthesis of GABA to glutamate, which is already increased in FXS.
Abbreviations: FMRP, fragile X mental retardation protein; FXS, fragile X syndrome; GABA, gamma-aminobutyric acid; GABA-T, gamma-aminobutyric acid transaminase; 
GAD, glutamic acid decarboxylase.
Aberrant Behavior Checklist-Community Edition, a 58-item 
behavioral questionnaire, did not show reduction in any of the 
subscales compared to placebo42 and, due to resource limitations, 
Seaside Therapeutics had to terminate its arbaclofen program.65 
However, a post hoc analysis saw a full study improvement on the 
Aberrant Behavior Checklist Social Avoidance subscale, which 
was an algorithm developed specifically to assess behavioral 
function in patients with FXS.66 In addition, a subgroup of 27 
patients with more severe social impairment treated with arba-
clofen showed improvement on all global measures, as well as on 
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the Vineland Socialization subscale, which is a semi-structured 
parent interview that assesses adaptive behavior. There were 
also trends of improvement seen on parent-nominated problem 
behaviors in the visual analog scale as well as on multiple global 
measures.42 This demonstrates the need to use biological subtyp-
ing, particularly in a heterogeneous group of patients, such as 
those with ASD. For the subgroup of patients with FXS who 
did very well with arbaclofen, it became a problem to obtain the 
drug once the company folded, and the withdrawal from arba-
clofen was very difficult for many families. Overall, arbaclofen 
was well tolerated, with sedation and headache being the most 
commonly reported side effects.42
Riluzole
Riluzole is a medication approved for the treatment of amyo-
trophic lateral sclerosis, which blocks voltage-gated Na+ chan-
nels and selectively depresses glutamate over GABA release 
and which, at higher concentrations, can potently increase 
postsynaptic GABA
A
 response in hippocampal neurons.67 
Due to the GABAergic dysregulation and epilepsy shown in 
patients with FXS, it was proposed that riluzole could act as a 
beneficial treatment for FXS. An open-label study of riluzole 
in patients with FXS showed a clinical response in only one 
of six patients, with significant improvement as measured on 
the ADHD Rating Scale-IV.43 Riluzole administration was also 
associated with significant correction of ERK activation time 
in all subjects. Overall, the medication was well tolerated and 
showed non-clinically significant increases in liver function 
tests,43 a notable side effect of the medication.
Tiagabine
Tiagabine, a nipecotic acid derivative, is another antiepilep-
tic that reduces neuronal and astrocytic uptake of GABA.68 
Sound-induced convulsions in DBA/2 mice – which, notably, 
had no sedation or motor debilitation70 – were corrected when 
tiagabine was administered;69 however, there have not been 
any studies assessing the efficacy of tiagabine in treating 
FXS. While it may be used to control epilepsy in patients 
with FXS, other antiepileptic medications seem to have more 
potent treatment responses.71
Conclusion
Numerous GABAergic compounds are potential treatments for 
FXS; however, considerably more basic and translational research 
is needed. The current studies are mostly open-label treatment 
options with small sample sizes of patients in a wide age range. 
Larger, double-blind, placebo-controlled trials are needed to 
assess the efficacy of these treatments against the placebo in order 
to better establish the treatment profile of each medication. The 
largest double-blind, placebo-controlled study using a GABAer-
gic compound in FXS used arbaclofen. Despite trends in a posi-
tive treatment response on secondary outcome measures, Seaside 
Therapeutics could not continue with additional studies focusing 
on the secondary outcome measures due to limited resources. 
This outcome brings to light the difficulty of establishing efficacy 
of targeted treatments in this population.42,72
A number of new treatments are also being studied in 
clinical trials after promising efficacy studies in the animal 
models of FXS.73 These include lovastatin, which lowers ERK 
phosphorylation in the mTOR pathway, and an insulin-like 
growth factor 1 analog made by Neuren (Neuren Phar-
maceuticals Limited, Camberwell, VIC, Australia). Other 
treatment trials are in the pipeline but have yet to come to 
clinical trials.74
There are a number of barriers to new treatments, 
including the time and expense of carrying out the toxicity 
studies in animals and humans and subsequent multicenter 
human trials to demonstrate efficacy. Although FXS is a 
single-gene disorder, there is significant heterogeneity in 
clinical involvement and response to treatment. For many 
trials, approximately 30% respond well, but this may not be 
adequate to demonstrate overall efficacy, which prohibits 
FDA approval for marketing. The lack of biomarkers that 
would predict efficacy is greatly needed so that a “likely to 
respond subgroup” could be identified.
For example, the AFQ056 compound by Novartis appears 
to be most effective for those who are fully methylated, but 
additional biomarkers are needed.75 In addition, outcome 
measures that are quantitative and relate to central nervous 
system function or molecular changes and do not depend on 
questionnaires from the family would be useful to decreas-
ing the placebo effect. Event-related potential paradigms of 
cognitive processing would also be useful, and we have seen a 
positive effect using the oddball paradigm and habituation task 
in children treated with minocycline in a controlled trial.76
The placebo effect is high, owing to the overwhelming 
need for effective interventions, which is further impacted by 
the difficulty of obtaining objective outcome measures that 
accurately assess a behavioral treatment response. A majority 
of the improvement measures were based on parent or caregiver 
response,42,66 which is  subjective. More objective outcome mea-
sures are needed, not only for GABAergic medications, but for 
all clinical trials that focus on neurodevelopmental indications. 
Biomarkers relating specifically to GABA upregulation in 
patients who did improve on the arbaclofen medication would 
be a vital tool for establishing efficacy against placebo.
Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1776
Lozano et al
Combined clinical trials using two drugs or a drug 
with an intervention program may show positive outcomes 
for FDA approval. A combined clinical trial of lovastatin 
with language intervention for individuals with FXS has 
been supported by the National Institute of Child Health 
and Human Development.77 GABA downregulation and 
mGluR5 upregulation are thought to be the major problems 
in FXS, so interventions in both of these pathways will be 
critical for an overall treatment program. Ganaxolone is 
currently undergoing a clinical trial in FXS and is consid-
ered to have the best potential as a GABA agent because 
it specifically targets the GABA
A
 pathway, which is most 
dysregulated in FXS. If efficacy in FXS is demonstrated 
and there is FDA approval for an FXS indication, then it 
will be studied in ASD and related disorders. Research 
needs to start focusing on multifaceted treatment options 
that combine multiple pharmacological agents and/or 
behavioral interventions due to the complex nature of the 
disease, but this may be difficult prior to FDA approval for 
each compound. Studies looking at behavioral and pharma-
cological interventions are planned for other targeted treat-
ment options in FXS, including the mGluR5 antagonists 
and lovastatin. No studies are currently planned for multiple 
GABAergic medications or GABAergic medications with 
behavioral interventions, which would be highly useful and 
may provide more outcome measures with which to gauge 
treatment response.
In addition to difficulties in outcome measures, it should 
also be noted that reversing the behavioral and intellectual 
abilities in FXS is more difficult in adults because they are 
not typically in a learning program and because the neuro-
biological abnormalities may be less reversible over time. 
More intensive learning programs are required, although 
the improvements seen in the adult mouse with FXS after 
treatment with a long-acting mGluR5 antagonist were 
remarkable78 and gave hope to many of the families that have 
adult offspring with FXS. Owing to the process involved in 
obtaining FDA approval for medications, companies must 
establish safety and efficacy in the adult population prior to 
moving into younger age groups; as such, the low efficacy 
of adult studies prevents the medication from moving to the 
younger age groups, who are more likely to see more robust 
treatment responses.
It is important to remember that synaptic connections that 
are strengthened by either a GABA agonist or an mGluR5 
antagonist also require an intensive learning environment to 
strengthen these connections. Although most school-aged 
children with FXS are receiving special education support 
in addition to speech and language therapy and occupational 
therapy, their programs can usually be enhanced by the use 
of digital learning programs that can be accessed on a tablet 
device. There are a variety of software applications that have 
been developed for individuals with ASD, and these programs 
are likely to also be helpful for those with FXS.79
There are many currently used medications that are 
helpful in FXS that will likely continue to be helpful even 
after GABA agonists and mGluR5 antagonists are more 
widely used clinically. These medications include sertra-
line, a selective serotonin reuptake inhibitor, that can be 
started at a young age and has been helpful in improving 
the language trajectory of toddlers with FXS.80 Another 
targeted treatment that can be effective at an early age 
is minocycline, which is an antibiotic that lowers the 
level of matrix metalloproteinase 9 which is elevated 
in FXS.81,82 High levels of matrix metalloproteinase 9 
interfere with the development of synaptic connections, 
and a controlled trial of minocycline in children between 
the ages of 3 and 17 years (doses ranging from 25 to 100 
mg per day) recently demonstrated efficacy on the CGI-I 
in improving overall behavior and on the visual analog 
scale for improving mood and anxiety.81 Side effects of 
minocycline include graying of the permanent teeth if 
given before 8 years of age, and graying or darkening of 
tissue such as in the gums and nail beds at any age. On rare 
occasions, minocycline can cause a lupus-like syndrome 
with a rash or swollen joints or pseudotumor cerebri leading 
to a severe headache; if these problems occur, minocycline 
should be discontinued immediately.81 Once children with 
FXS reach 5 years of age, they usually have a positive 
response to a stimulant for their ADHD symptoms; for 
those who do not respond to a stimulant, then an alpha 
agonist such as guanfacine can be very helpful.32 Lastly, 
melatonin has also been helpful for sleep disturbances in 
FXS, particularly in young children.83 Overall, a GABA 
agonist will add significantly to the treatment regimen in 
children and adults with FXS, although we do not yet know 
if improvements will be seen only in behavior or if cognitive 
deficits will also improve with long-term use.
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